TriangleCAR-T cell (NCT05003895)
CAR-T cell trial for Hepatocellular Carcinoma (NCT05003895). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
Hepatocellular carcinoma is among the deadliest cancers worldwide; once it spreads, treatments add months, not years.
The idea: a marker found on nearly every liver cancer cell but not on healthy adult liver, as a target for engineered T cells.
That marker is glypican-3. At the NIH Clinical Center, a patient's T cells are collected, given a humanized receptor for glypican-3, and returned in a single infusion after three days of chemotherapy clears space. Because the protein is absent from normal liver, the hope is that the cells attack tumor and spare the organ around it.
An early safety study for adults whose tumor tests positive, including other cancers carrying the marker. Tim Greten leads it in Bethesda. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.